Gastroenterology

Pancreatic tumors become susceptible to toxin when made to express IL-13Ralpha2

Published in Gene Therapy Weekly, July 31st, 2003

by Sonia Nichols, senior medical writer - Patients diagnosed with pancreatic cancer could some day be cured by gene therapy that makes their tumors more vulnerable to a recombinant cytotoxin.

Researchers at the U.S. Food and Drug Administration have taken advantage of the ligand binding and internalization properties of interleukin-13 receptor (IL-13R)alpha2 to make pancreatic tumor cells more susceptible to the cytotoxic effects of recombinant IL-13. In addition to killing tumors directly, the therapy may activate a tumor immune response, study authors say.

"For this, a plasmid encoding the IL-13Ralpha2 chain gene was mixed with liposomes and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-07-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry